Skip to content

Echocardiography in Critically-ill Patients With COVID-19 Pneumonia

Echocardiography in Critically-ill Patients With COVID-19 Pneumonia

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04414410
Acronym
ECHO-COVID
Enrollment
1500
Registered
2020-06-04
Start date
2020-05-12
Completion date
2021-09-30
Last updated
2021-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID, Sars-CoV2

Keywords

critical care echocardiography, COVID, pneumonia, ICU

Brief summary

Critical care echocardiography (CCE) has been widely used since the 10 last years. Covid outbreak leads that many patients with acute respiratory failure were admitted in the ICU. Many of these patients were ventilated and developed ARDS. Some of them developed deep vein thrombosis and pulmonary embolism. Nothing is already described about the cardiac function and the hemodynamics in these patients (how many RV failure, LV systolic dysfunction,...). The echo group of the cardiodynamix section of European society of intensive care medicien (ESICM) aims to promote CCE and evaluate its interest. The objective is to retrospectively enter in an international database all the echo studies done as usual care in these patients to evaluate (i) incidence of RV failure, (ii) incidence of LV systolic function, (iii) incidence of other patterns. Another objective will be to look for any association between some patterns and respiratory strategy, blood gas analysis, systemic hemodynamics. The echo studies were done and will be reported following one of the recent systematic review published by the same group (Huang S et al. AOIC 2020).

Detailed description

Multicenter, international observational retrospective study. Patients admitted in the ICU between March 1th and april 26th for a pneumonia related to SARS COV 2 and who had at least one echocardiography during their stay will be included. Analysis will be retrospective in order to report the hemodynamic profile with left ventricular and right ventricular function. Will be also reported the respiratory settings, the central venous presure if available as well as usual parameters of macrocirculation. All data will be reported in RedCap by the University of sydney (https://redcap.sydney.edu.au/).

Interventions

None listed

Sponsors

Hospital Ambroise Paré Paris
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL

Inclusion criteria

patients admitted in the ICU for pneumonia related to SARS COV2 and who had at least 1 critical care echocardiography during the first 28 days. \-

Exclusion criteria

Patients who did not have any critical care echocardiography during the first 28 days of the ICU stay.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of Left ventricular systolic dysfunctionUp to 28 daysLV systolic dysfunction is defined as an ejection fraction \< 45%
Incidence of RV failureup to 28 daysRV failure is defined as RV/LV end-diastolic area \> 0.8
Incidence of VasoplegiaUp to 28 daysVasoplegia is defined as a normal or supranormal LV ejection fraction without echocarduiographic signs of hypovolemia.
Incidence of HypovolemiaUp to 28 daysHypovolemia is defined as inspiratory collaspe of the superior vena cava in ventilated patients or virtual inferior vena cava in spontaneously breathing patients.

Secondary

MeasureTime frameDescription
Relation between plateau pressure and RV failureUp to 28 daysPlateau pressure and RV size
Relation between PEEP and RV failureUp to 28 daysPEEP and RV size
Relation between tidal volume and RV failureUp to 28 daysTidal volume and RV size
Relation between PaO2 and RV failureUp to 28 daysPaO2, PaO2/FiO2, and RV size
Relation between PaCO2 and RV failureUp to 28 daysPaCO2 and RV size

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026